Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CLPP | Q16740 | 1/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489713 | 0.89 | CCR2 (0.38) | CCR2AKR1B1ABCB11P2RX7LMNA | |
| SCHEMBL1335830 | 0.88 | AKR1B1 (0.37) | CCR2AKR1B1ABCB11TP53P2RX7 | |
| SCHEMBL4477879 | 0.83 | MEN1 (0.38) | AKR1B1MAPTP2RX7LMNAHTT | |
| SCHEMBL1337872 | 0.82 | MEN1 (0.35) | AKR1B1TP53MAPTP2RX7LMNA | |
| SCHEMBL4480439 | 0.82 | P2RX7 (0.35) | AKR1B1P2RX7SMN1; SMN2 | |
| SCHEMBL1335967 | 0.81 | P2RX7 (0.36) | AKR1B1TP53MAPTP2RX7LMNA | |
| SCHEMBL1338069 | 0.81 | MEN1 (0.34) | AKR1B1TP53MAPTP2RX7LMNA | |
| SCHEMBL1336948 | 0.80 | AKR1B1 (0.38) | CCR2AKR1B1P2RX7SMN1; SMN2 | |
| SCHEMBL4486261 | 0.80 | P2RX7 (0.37) | P2RX7LMNAHTTSMN1; SMN2 | |
| SCHEMBL4482091 | 0.80 | FSCN1 (0.34) | AKR1B1TP53MAPTP2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | CCR2 2233/4885AKR1B1 2248/4885ABCB11 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.